<DOC>
	<DOCNO>NCT02686177</DOCNO>
	<brief_summary>GLP-1 receptor agonist introduce treatment type 2 Diabetes ( T2D ) efficacy document . However , safety aspect also important evaluate respect micro macrovascular complication associate T2D . Few study properly address role GLP-1-based therapy regulate vascular integrity angiogenesis . The study evaluate impact one-month treatment Liraglutide ANGPT2 ANGLPT4 level endothelial circulate progenitor cell , angiogenesis biomarkers type 2 diabetic patient .</brief_summary>
	<brief_title>Effect GLP-1 Angiogenesis</brief_title>
	<detailed_description>GLP-1 receptor agonist introduce treatment type 2 Diabetes ( T2D ) efficacy document . Beside therapeutic benefit , direct cardiovascular effect also report . However , safety aspect also important evaluate respect micro macrovascular complication associate T2D . T2D patient treat GLP-1 analog may suffer microvascular complication macular oedema proliferative retinopathy , characterize excessive retinal angiogenesis . Few study properly address role GLP-1-based therapy regulate vascular integrity angiogenesis . The role GLP-1 endothelial cell ( EC ) growth , EC integrity angiogenesis thus need characterize . Our aim provide proof concept agonists GLP-1 regulate angiogenesis human identify underlying mechanism . The present project translational part ANR Angiosafe-T2D , regard clinical safety aspects GLP-1 receptor agonist ( namely Liraglutide ) angiogenesis . The study evaluate impact one-month treatment Liraglutide ANGPT2 ANGLPT4 level endothelial circulate progenitor cell , angiogenesis biomarkers type 2 diabetic patient .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetic patient ( ADA criterion ) Age &gt; 18 year Obesity ( BMI &gt; = 30 kg/m2 ) HbA1c &gt; 7 % Treatment Metformin and/or secretagogues Effective contraception ( woman ) Treatment Exenatide , Liraglutide incretinergic regimen ( &lt; 1 month recruitment ) Type 1 diabetes acute disease infection chronic renal failure ( MDRD eGFRâ‰¤50 mL/min ) recent cardiovascular event surgery ( &lt; 3 month ) pancreatitis history antiVEGF treatment untreated cancer immunological disorder pregnancy lactation Vulnerable people : deprivation Liberty safeguard hypersensitivity active substance excipients investigational drug diabetic ketoacidosis heart failure stage 3 4 ( NYHA IIIIV ) Hepatic insufficiency inflammatory bowel disease gastroparesis No affiliation social security</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Angiogenesis</keyword>
	<keyword>Liraglutide</keyword>
	<keyword>Glucagon like peptide 1 receptor agonist</keyword>
</DOC>